Salestools LogoSalestools
Salestools KI-Agenten
Lösungen
Ressourcen
Unternehmen
Preise
Salestools Logo

Salestools

Der #1 KI-Agent für Vertriebsteams und Go-to-Market-Teams. Verkaufen Sie mehr, schneller, mit weniger Aufwand.

Produkt

  • KI-Vertriebsagenten
  • Intent-Daten
  • Technologiedaten
  • Besucher-Tracking
  • Co-Pilot
  • Social Selling

Lösungen

  • Kundenservice
  • E-Commerce
  • SaaS
  • Enterprise
  • Kleinunternehmen

Ressourcen

  • Der Report
  • Dokumentation
  • API-Referenz
  • Hilfecenter
  • Blog
  • Fallstudien
  • Webinare

Unternehmen

  • Über uns
  • Karriere
  • Presse
  • Kontakt
  • Partner

Unsere Standorte

  • New York, HQ
  • Bukarest, KI-Forschungslabor
  • Zug, Schweiz

© 2026 Salestools. Alle Rechte vorbehalten.

Datenbedingungen & SicherheitDatenschutzerklärungNutzungsbedingungenAcceptable Use
Alle Systeme betriebsbereit
Salestools LogoSalestools
Salestools KI-Agenten
Lösungen
Ressourcen
Unternehmen
Preise
Back to Reports
Fundraising

Checkr

Checkr Raises $250M in Series E

548 Market Street, San Francisco, CA 94104September 15, 20242 min read
Employees
800+

Checkr Raises $250M in Series E


Checkr has successfully raised $250M in a Series E at a $5B valuation led by Coatue, T. Rowe Price, Durable Capital Partners, Y Combinator, Accel, IVP, Tiger Global.


Company Overview


Checkr is a HR Tech company headquartered in 548 Market Street, San Francisco, CA 94104, founded in 2014 with 800+ employees.


Background check platform


Fundraising Details


  • Amount Raised: $250M
  • Round Type: Series E
  • Valuation: $5B
  • Date: 2024-09-15
  • Investors: Coatue, T. Rowe Price, Durable Capital Partners, Y Combinator, Accel, IVP, Tiger Global

About Checkr


Background check platform The company is positioned in the HR Tech sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: 548 Market Street, San Francisco, CA 94104
  • Founded: 2014
  • Team Size: 800+
  • Industry: HR Tech

What This Means


This funding round demonstrates strong investor confidence in Checkr's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The HR Tech sector continues to attract significant investment as companies innovate to meet evolving market demands. Checkr's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $5B valuation marks an important milestone for Checkr, positioning the company among notable players in the HR Tech industry.


Looking Ahead


With this new capital, Checkr is well-positioned to execute on its growth strategy and continue building innovative solutions in the HR Tech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2024-09-15. For more information about Checkr, visit their headquarters at 548 Market Street, San Francisco, CA 94104.

Company Info

Headquarters
548 Market Street, San Francisco, CA 94104
Founded
2014
Team Size
800+

Topics

Fundraising(2912)HR Tech(290)Series ECheckr

Share

Related Reports

Fundraising
Tebra

Tebra Raises $250M Growth Financing | Healthcare Practice Management Platform

Healthcare practice management platform Tebra secures $250 million in growth financing led by Hildred Capital for AI-driven automation.

SalesTools Research
SalesTools Research
Jan 12, 2026
0 min read•$250M
Fundraising
Harmattan AI

Harmattan AI Raises $200M Series B | Defense Tech Unicorn at $1.4B Valuation

French defense tech company Harmattan AI secures $200 million Series B led by Dassault Aviation, reaching unicorn status.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M
Fundraising
AirNexis Therapeutics

AirNexis Therapeutics Raises $200M Series A | Novel COPD Treatment

Biotech AirNexis Therapeutics emerges from stealth with $200 million Series A for dual PDE3/4 inhibitor COPD therapy.

SalesTools Research
SalesTools Research
Jan 11, 2026
0 min read•$200M

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free